Motif Pharmaceuticals Ltd. 13D and 13G filings for Chromocell Therapeutics Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-01 5:10 pm Purchase | 2024-02-21 | 13G | Chromocell Therapeutics Corporation CHRO | Motif Pharmaceuticals Ltd. | 483,406 8.400% | 483,406 (New Position) | Filing |